OpenClinica, an open source EDC system, to hit the Italian market thanks to a new partnership.
Cambridge, MA-June 12th, 2008-Conecta, an Italian open source consulting company, and Akaza Research, developers of OpenClinica, the leading open source Electronic Data Capture (EDC) software, jointly announce a development partnership aimed at bringing OpenClinica and OpenClinica Enterprise to the Italian clinical research market.
"OpenClinica is the most advanced open source EDC system in the market today", said Carlo Daffara, research director at Conecta. "After extensive evaluation, we found the tool to be flexible, complete, and well developed according to best practices in the clinical research software market. The flexibility of open source and the validated approach help in bringing EDC to new markets that have been until now, locked into proprietary and inflexible solutions."
”We are pleased to be working with Conecta,” said Benjamin Baumann, director of business development at Akaza Research. “This partnership will further strengthen OpenClinica’s presence across Europe, allowing more researchers to benefit from a professionally supported open source solution.”
OpenClinica is already in trial use at the Disability Italian Network and the Tuscany Region, in a specialized study based on the WHO ICF protocol, and is being implemented for the Regional Health Care Authority of the Friuli-Venezia Giulia region. An early outcome is the development of an Italian localization of OpenClinica that is expected to be included in the next production release of the product. In addition, the groups will share code and best practices for the dynamic forms and complex validation functionalities.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.